VistaGen Therapeutics, Inc.
VTGN · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $486 | $1,064 | -$227 | $1,109 |
| % Growth | -54.3% | 568.7% | -120.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $486 | $1,064 | -$227 | $1,109 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $39,375 | $20,022 | $44,377 | $35,408 |
| G&A Expenses | $17,084 | $14,063 | $14,664 | $10,452 |
| SG&A Expenses | $17,084 | $14,063 | $14,664 | $13,248 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $2,796 |
| Other Operating Expenses | $0 | $0 | $0 | $232 |
| Operating Expenses | $56,459 | $34,085 | $59,041 | $48,888 |
| Operating Income | -$55,973 | -$33,021 | -$59,268 | -$47,779 |
| % Margin | -11,517.1% | -3,103.5% | 26,109.3% | -4,308.7% |
| Other Income/Exp. Net | $4,562 | $3,663 | $26 | $20 |
| Pre-Tax Income | -$51,411 | -$29,358 | -$59,242 | -$47,759 |
| Tax Expense | $7 | $4 | $6 | $3 |
| Net Income | -$51,418 | -$29,362 | -$59,248 | -$47,762 |
| % Margin | -10,579.8% | -2,759.6% | 26,100.4% | -4,307.2% |
| EPS | -1.67 | -1.52 | -8.51 | -7.38 |
| % Growth | -9.9% | 82.1% | -15.3% | – |
| EPS Diluted | -1.67 | -1.52 | -8.51 | -7.38 |
| Weighted Avg Shares Out | 30,712 | 19,355 | 6,959 | 6,599 |
| Weighted Avg Shares Out Dil | 30,712 | 19,355 | 6,959 | 6,599 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,557 | $3,351 | $49 | $20 |
| Interest Expense | $0 | $0 | $23 | $0 |
| Depreciation & Amortization | $635 | $568 | $532 | $711 |
| EBITDA | -$55,338 | -$32,453 | -$58,736 | -$47,048 |
| % Margin | -11,386.4% | -3,050.1% | 25,874.9% | -4,242.8% |